2025-05-20-Jefferies-Givaudan(GIVN)_奇华顿首席执行官炉边谈话反馈_7页_112kb
报告摘要
Summary of Givaudan Equity Research Report
Rating: UNDERPERFORM
Price Target: CHF3,500
Key Messages
- Despite challenges from tough comparables and trade uncertainties, Givaudan remains confident in growth at CHF4,118, supported by customer innovation priorities and no evidence of pre-buying. EBITDA margin target of >24% is achievable despite a 4% raw material cost rise.
- Confident growth outlook operational is maintained, with no impacts from pre-buying identified. Innovation pipeline in consumer fragrances shows strength, contrary to weaker consumer behavior commentary from some competitors.
Operational Highlights
- Fine fragrances show limited behavioral changes, but higher dosage levels in consumer fragrances highlight customer innovation focus. Unilever's in-house fragrance efforts underscore the specialized nature of fragrance creation, where Givaudan's R&D and perfumery expertise provide a differentiator.
- Taste & Wellbeing segment grows faster among regional clients; health and wellbeing solutions drive momentum in mature markets.
Strategic Focus
- Consumer fragrances are a key strategic area with scent as a competitive differentiator, aided by internal innovation capabilities. AI tools like 'Smart Submission' support briefs in regions like Southeast Asia.
- Growth opportunities in taste and wellbeing continue, with dairy-based plant-based products performing well. M&A is open for bolt-on opportunities, particularly in health/well-being or biotechnology-driven spaces.
Financial Position
- Givaudan is healthy in balance sheet (ND/EBITDA ~2.3x). Open to small-to-medium acquisitions given reputation for successful integrations, though limited interest in adjacent low-value areas or general ingredients.
- M&A execution risk is noted, alongside balance sheet expansion potential. Valuation upside risks include successful M&A, lower bond yields, and no significant competition changes.
Valuation and Risks
- Current valuation at CHF3,500 via DCF and SOTP methods. Risks include poor M&A outcomes, global competition dynamics, and economic factors like bond yields. Givaudan underperforms relative to growth expectations in the chemical sector.
展开完整摘要
试读结束,高清完整版pdf/doc/ppt,请点下载